Nicholas Duperry Clinton LD 1847

Testimony in Opposition to LD 1847

*Do Not Pass

Presented to the Committee on Veterans and Legal Affairs

Date: 5-5-2025

Submitted by: Nicholas Duperry

Chairperson and Members of the Committee,

I am writing in strong opposition to LD 1847, a bill that would impose unnecessary regulatory burdens on Maine's medical cannabis community. These proposed requirements would harm small caregivers, drive up costs for patients, and disrupt an industry that has provided essential healthcare and economic stability.

The bill forces medical cannabis providers to adhere to tracking and testing requirements designed for the adult-use market, disregarding the distinct needs of medical patients and caregivers. Small-scale providers, many of whom operate on tight margins, will face compliance costs they cannot afford, leading to closures, job losses, and limited patient access. The effect will be the consolidation of the industry under large corporate entities, eliminating the personalized care that has been the foundation of Maine's medical cannabis program.

Dedicating a portion of adult-use cannabis tax revenue to medical programs does nothing to protect patient access or affordability. Medical cannabis should not be treated as an afterthought, nor should patients be forced to shoulder increased costs for the sake of regulatory uniformity. Maine's medical cannabis program is built on accessibility, community-driven care, and patient autonomy—this bill threatens to dismantle that model.

LD 1847 prioritizes bureaucratic control over the well-being of patients and caregivers. The legislature should reject this harmful proposal and preserve Maine's medical cannabis program without forcing unnecessary financial strain on the people who depend on it.

Sincerely, Nicholas Duperry